Comorbidities And Complications Associated With Covid-19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04563442|
Recruitment Status : Not yet recruiting
First Posted : September 24, 2020
Last Update Posted : September 24, 2020
|Condition or disease||Intervention/treatment|
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a coronavirus with human infection designated as COVID-19 by the World Health Organization. Bats and birds serve as the typical coronavirus hosts, with zoonotic spread and a long-documented history of animal-animal-human transmission.  Since November 2019, the rapid outbreak of coronavirus disease 2019 (COVID-19), which arose from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has recently become a public health emergency of international concern . COVID-19 has contributed to an enormous adverse impact globally.
As of 10 March 2020 there have been 113702 laboratory confirmed cases and 4012 deaths globally .
According to the latest reports, the clinical manifestations of COVID-19 are heterogeneous [4-6]. On admission, 20-51% of patients were reported as having at least one comorbidity, with diabetes (10-20%), hypertension (10-15%) and other cardiovascular and cerebrovascular diseases (7-40%) being most common [4, 5, 7]. Previous studies have demonstrated that the presence of any comorbidity has been associated with a 3.4-fold increased risk of developing acute respiratory distress syndrome in patients with H7N9 infection . As with influenza [9, 10], SARS-CoV  and Middle East Respiratory Syndrome coronavirus (MERS-CoV) , COVID-19 is more readily predisposed to respiratory failure and death in susceptible patients [5, 6].
Although it is well documented that COVID-19 is primarily manifested as a respiratory tract infection, emerging data indicate that it should be regarded as a systemic disease involving multiple systems, including cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immune system.  Mortality rates of COVID-19 are lower than SARS and Middle East Respiratory Syndrome (MERS) ; however, COVID-19 is more lethal than seasonal flu.
Older people and those with comorbidities are at increased risk of death from COVID-19, but younger people without major underlying diseases may also present with potentially lethal complications such as fulminant myocarditis and disseminated intravascular coagulopathy (DIC) .
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Comorbidities And Complications Associated With Covid-19 Infection|
|Estimated Study Start Date :||October 15, 2020|
|Estimated Primary Completion Date :||October 15, 2022|
|Estimated Study Completion Date :||February 25, 2023|
complications and comorbidities
complication co morbidities
- Identifying different co-morbidities and complications of covid-19 infection. [ Time Frame: baseline ]Identifying and management of different co-morbidities and complications of covid-19 infection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04563442
|Contact: Mahmoud Gamal email@example.com|
|Contact: Gamal Mohamed Rabee||01221729476||Gamalagmy135@gmail.com|